Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Express Scripts
McKinsey
Colorcon
AstraZeneca

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,759,506

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,759,506
Title:Expression enhancing intron sequences
Abstract: The invention relates to methods for the identification and use of introns with gene expression enhancing properties. The teaching of this invention enables the identification of introns causing intron-mediated enhancement (IME) of gene expression. The invention furthermore relates to recombinant expression construct and vectors comprising said IME-introns operably linked with a promoter sequence and a nucleic acid sequence. The present invention also relates to transgenic plants and plant cells transformed with these recombinant expression constructs or vectors, to cultures, parts or propagation material derived there from, and to the use of same for the preparation of foodstuffs, animal feeds, seed, pharmaceuticals or fine chemicals, to improve plant biomass, yield, or provide desirable phenotypes.
Inventor(s): Song; Hee-Sook (Raleigh, NC), Dammann; Christian (Durham, NC), Morra; Marc (Bronx, NY), Brown; Jeffrey A. (Apex, NC), Xing; Liqun (Chapel Hill, NC), Jia; Hongmei (Apex, NC)
Assignee: BASF Plant Science GmbH (Ludwigshafen, DE)
Application Number:13/241,493
Patent Claims:1. A recombinant DNA expression construct comprising: a) at least one promoter sequence functioning in plants or plant cells; b) at least one intron comprising the sequence of SEQ ID NO: 2 or a functional equivalent thereof; and c) at least one nucleic acid sequence, wherein the at least one promoter sequence and at least one intron are functionally linked to the at least one nucleic acid sequence, wherein the at least one intron is heterologous to the at least one nucleic acid sequence and/or to the at least one promoter sequence, and wherein the functional equivalent thereof increases gene expression and comprises a sequence having at least 80% sequence identity to the full-length sequence of SEQ ID NO: 2 and comprises I) an intron length shorter than 1000 base pairs, and II) a 5' splice site comprising the dinucleotide sequence 5'-GT-3' (SEQ ID NO: 78), and III) a 3' splice site comprising the trinucleotide sequence 5'-CAG-3' (SEQ ID NO: 79), and IV) a branch point resembling the consensus sequence 5'-CURAY-3' (SEQ ID NO: 75) upstream of the 3' splice site.

2. The recombinant DNA expression construct of claim 1, wherein the functional equivalent comprises i) an adenine plus thymine content of at least 40% over 100 nucleotides downstream from the 5' splice site, and ii) an adenine plus thymine content of at least 50% over 100 nucleotides upstream from the 3' splice site, and iii) an adenine plus thymine content of at least 55%, and a thymine content of at least 30% over the entire intron.

3. The recombinant DNA expression construct of claim 1, wherein the functional equivalent comprises a sequence having at least 90% sequence identity to the full-length sequence of SEQ ID NO: 2.

4. The recombinant DNA expression construct of claim 1, wherein the functional equivalent comprises a sequence having at least 95% sequence identity to the full-length sequence of SEQ ID NO: 2.

5. The recombinant DNA expression construct of claim 1, wherein the at least one intron comprises the sequence of SEQ ID NO: 2.

6. The recombinant DNA expression construct of claim 1, wherein said nucleic acid encodes i) a protein or ii) a sense, antisense, or double-stranded RNA sequence.

7. The recombinant DNA expression construct of claim 1, wherein said promoter sequence functioning in plants or plant cells is selected from the group consisting of a) a promoter comprising nucleotides 1 to 854 of SEQ ID NO: 113, or a sequence having at least 95% identity to nucleotides 1 to 854 of SEQ ID NO: 113, or a sequence comprising at least 300 consecutive nucleotides of SEQ ID NO: 113, b) a promoter comprising nucleotides 1 to 1184 of SEQ ID NO: 114, or a sequence having at least 95% identity to nucleotides 1 to 1184 of SEQ ID NO: 114, or a sequence comprising at least 300 consecutive nucleotides of SEQ ID NO: 114, c) a promoter comprising nucleotides 1 to 1034 of SEQ ID NO: 115, or a sequence having at least 90% identity to nucleotides 1 to 1034 of SEQ ID NO: 115, or a sequence comprising at least 200 consecutive nucleotides of SEQ ID NO: 115, d) a promoter comprising nucleotides 1 to 1440 of SEQ ID NO: 116, or a sequence having at least 95% identity to nucleotides 1 to 1440 of SEQ ID NO: 116, or a sequence comprising at least 50 300 consecutive nucleotides of SEQ ID NO: 116, e) a promoter comprising nucleotides 1 to 1589 of SEQ ID NO: 117, or a sequence having at least 90% identity to nucleotides 1 to 1589 of SEQ ID NO: 117, or a sequence comprising at least 200 consecutive nucleotides of SEQ ID NO: 117, f) a promoter comprising nucleotides 1 to 796 of SEQ ID NO: 118, or a sequence having at least 95% identity to nucleotides 1 to 796 of SEQ ID NO: 118, or a sequence comprising at least 300 consecutive nucleotides of SEQ ID NO: 118, g) a promoter comprising nucleotides 1 to 1062 of SEQ ID NO: 119, or a sequence having at least 95% identity to nucleotides 1 to 1062 of SEQ ID NO: 119, or a sequence comprising at least 50 300 consecutive nucleotides of SEQ ID NO: 119, and h) a promoter comprising nucleotides 1 to 1386 of SEQ ID NO: 121, or a sequence having at least 95% identity to nucleotides 1 to 1386 of SEQ ID NO: 121, or a sequence comprising at least 300 consecutive nucleotides of SEQ ID NO: 121.

8. An expression vector comprising the recombinant DNA expression construct of claim 1.

9. A transgenic cell or transgenic non-human organism or a cell culture, part or propagation material derived therefrom comprising the expression construct of claim 1 or a vector comprising the expression construct, wherein the cell or non-human organism is from a bacterium or plant.

10. The transgenic cell or non-human organism of claim 9, wherein said cell or organism is a monocotyledonous plant cell or organism selected from the group consisting of the genera Hordeum, Avena, Secale, Triticum, Sorghum, Zea, Saccharum, and Oryza.

11. A method for providing an expression cassette for enhanced expression of a nucleic acid sequence in a plant or a plant cell or for enhancing the expression of a nucleic acid sequence in a plant or a plant cell, said method comprising the step of functionally linking the at least one intron as described in claim 1 to a nucleic acid sequence.

12. The method of claim 11, wherein said nucleic acid sequence encodes a selectable marker protein, a screenable marker protein, an anabolic active protein, a catabolic active protein, a biotic or abiotic stress resistance protein, a male sterility protein, a protein affecting plant agronomic characteristics, or a sense, antisense, or double-stranded RNA.

13. The method of claim 11, wherein the functional equivalent comprises a sequence having at least 95% sequence identity to the full-length sequence of SEQ ID NO: 2.

14. The method of claim 11, wherein the at least one intron comprises the sequence of SEQ ID NO: 2.

15. The method of claim 11, further comprising the step of linking a promoter functional in plants to the nucleic acid sequence.

16. The method of claim 11 wherein the plant is a monocotyledonous plant or the plant cell is from a monocotyledonous plant.

17. A method for producing a transgenic plant or plant cell, said method comprising the step of transforming a plant or plant cell with the recombinant DNA expression construct of claim 1, and optionally regenerating a plant from the transformed plant cell.

18. The method of claim 17, wherein the plant is a monocotyledonous plant or the plant cell is from a monocotyledonous plant.

Details for Patent 8,759,506

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial BASF Plant Science GmbH (Ludwigshafen, DE) 2025-03-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial BASF Plant Science GmbH (Ludwigshafen, DE) 2025-03-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial BASF Plant Science GmbH (Ludwigshafen, DE) 2025-03-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
Baxter
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.